FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to the propofol anesthetic composition suitable for parenteral administration. The composition comprises propofol in the concentration from 1 mg/ml to 20 mg/ml, d-alpha-tocopheryl polyethylene glycol-1000 succinate (TPGS) in the concentration from 10 mg/ml to 200 mg/ml, and water. The mass ratio of propofol to TPGS is at least 1:10. The composition is sterilized by final sterilization in autoclave. The present composition overcomes shortcomings of the ready preparative formulation in the emulsion form, namely, it provides the stable clear product in storage under regulated temperature conditions, i. e . in cooling.
EFFECT: improved and valuable pharmaceutical properties of composition.
11 cl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS | 2009 |
|
RU2522977C2 |
| COMPOSITIONS AND WAYS OF PHARMACOLOGICAL AGENTS DELIVERY | 2003 |
|
RU2361615C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING WATER SOLUBLE PROPOPHOL PRODRUGS AND USES THEREOF | 2003 |
|
RU2297216C2 |
| PHARMACEUTICAL COMPOSITIONS OF WATER-SOLUBLE PROPOPHOL PROMEDICINES COMPOSED UPON WATER FOUNDATION | 2002 |
|
RU2316317C2 |
| PROPOFOL DELIVERY SYSTEMS | 2016 |
|
RU2709812C2 |
| COMPOSITION OF BCL-2 INHIBITOR BASED ON CYCLODEXTRIN | 2019 |
|
RU2804366C2 |
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2824132C2 |
| PROPOFOL-CONTAINING COMPOSITION WITH ENHANCED ANTIBACTERIAL EFFECT | 2001 |
|
RU2244545C2 |
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2667010C2 |
| PHARMACEUTICAL COMPOSITION FOR PARENTERAL DELIVERY IN FORM OF LYOPHILIZATE AND METHOD OF ITS OBTAINING | 2007 |
|
RU2370258C2 |
